Ken Mackie Selected Research

3- (1,1- dimethyl- heptyl)- 1- hydroxy- 9- methoxy- benzo(c)chromen- 6- one

1/2022	A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.
1/2019	Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.
3/2015	Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ken Mackie Research Topics

Disease

25	Pain (Aches) 01/2022 - 01/2006
12	Hyperalgesia 01/2022 - 12/2010
12	Neuralgia (Stump Neuralgia) 01/2021 - 12/2006
8	Inflammation (Inflammations) 01/2022 - 03/2010
6	Neuroinflammatory Diseases 01/2021 - 03/2005
5	Neoplasms (Cancer) 03/2021 - 05/2015
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 01/2011
4	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 03/2005
4	Fibrosis (Cirrhosis) 01/2018 - 03/2010
4	Obesity 09/2017 - 05/2005
3	Chronic Pain 12/2021 - 04/2007
3	Neurocognitive Disorders (Clerambault Syndrome) 12/2019 - 01/2016
3	Huntington Disease (Huntington's Disease) 01/2018 - 04/2010
3	Substance-Related Disorders (Drug Abuse) 09/2017 - 01/2008
3	Hypersensitivity (Allergy) 01/2017 - 04/2014
3	Atherosclerosis 03/2012 - 10/2007
3	Seizures (Absence Seizure) 01/2007 - 07/2006
3	Febrile Seizures (Febrile Seizure) 01/2007 - 08/2003
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2022 - 01/2018
2	Temporal Lobe Epilepsy 01/2022 - 07/2010
2	Cognitive Dysfunction 01/2022 - 01/2016
2	Opioid-Related Disorders (Opiate Addiction) 10/2021 - 01/2018
2	Necrosis 01/2021 - 06/2010
2	Marijuana Abuse (Cannabis Abuse) 01/2020 - 04/2012
2	Fasciculation (Fasciculations) 12/2019 - 09/2010
2	Glioma (Gliomas) 01/2018 - 01/2017
2	Pathologic Processes 01/2018 - 04/2012
2	Disease Progression 04/2017 - 04/2011
2	Schizophrenia (Dementia Praecox) 01/2017 - 06/2014
2	Insulin Resistance 01/2016 - 05/2010
2	Metabolic Diseases (Metabolic Disease) 01/2016 - 04/2014
2	Hypothermia 07/2015 - 03/2015
2	Fragile X Syndrome (Martin Bell Syndrome) 08/2013 - 01/2012
2	Cardiovascular Diseases (Cardiovascular Disease) 06/2010 - 03/2010
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2022
1	Closed Head Injuries 01/2022
1	Respiratory Insufficiency (Respiratory Failure) 10/2021
1	Glioblastoma (Glioblastoma Multiforme) 03/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Hypoxia (Hypoxemia) 01/2021

Drug/Important Bio-Agent (IBA)

42	EndocannabinoidsIBA 01/2022 - 08/2003
30	CannabinoidsIBA 10/2021 - 08/2003
24	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022 - 12/2006
11	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2021 - 07/2006
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 03/2015
8	EnzymesIBA 01/2022 - 06/2010
7	anandamide (arachidonylethanolamide)IBA 01/2016 - 10/2004
6	Dronabinol (THC)FDA LinkGeneric 03/2021 - 09/2003
5	CB2 Cannabinoid ReceptorIBA 01/2022 - 09/2003
5	Opioid Analgesics (Opioids)IBA 12/2021 - 01/2018
5	Analgesics (Analgesic Drugs)IBA 10/2021 - 12/2006
5	Morphine (MS Contin)FDA LinkGeneric 01/2021 - 06/2015
5	Proteins (Proteins, Gene)FDA Link 12/2019 - 03/2007
5	LigandsIBA 05/2015 - 05/2005
4	CB2 receptor agonist LY2828360IBA 01/2022 - 01/2018
4	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 01/2022 - 12/2006
4	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 06/2010
3	3- (1,1- dimethyl- heptyl)- 1- hydroxy- 9- methoxy- benzo(c)chromen- 6- oneIBA 01/2022 - 03/2015
3	Cannabinoid Receptor AgonistsIBA 10/2021 - 07/2012
3	OrexinsIBA 01/2021 - 10/2011
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 05/2005
3	Freund's AdjuvantIBA 01/2019 - 01/2017
2	Monoacylglycerol LipasesIBA 01/2022 - 04/2011
2	Pharmaceutical PreparationsIBA 10/2021 - 06/2010
2	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 04/2017
2	Oxygen (Dioxygen)IBA 01/2021 - 03/2010
2	Formaldehyde (Formol)FDA Link 01/2020 - 06/2015
2	3- (2- nitro- 1- phenylethyl)- 2- phenyl- 1H- indoleIBA 01/2020 - 11/2018
2	pyrazolanthroneIBA 01/2020 - 06/2015
2	LipidsIBA 01/2019 - 04/2012
2	gamma-Aminobutyric Acid (GABA)IBA 11/2018 - 08/2003
2	GTP-Binding Proteins (G-Protein)IBA 01/2018 - 04/2012
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 04/2017 - 06/2010
2	Ethanol (Ethyl Alcohol)IBA 01/2017 - 05/2007
2	RimonabantIBA 07/2015 - 09/2003
2	HydrolasesIBA 12/2013 - 04/2011
2	Glutamic Acid (Glutamate)FDA Link 07/2012 - 01/2012
2	JNK Mitogen-Activated Protein KinasesIBA 03/2012 - 06/2010
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2012 - 10/2007
2	Peroxidase (Myeloperoxidase)IBA 08/2011 - 05/2009
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 09/2010 - 01/2006
2	NitrogenIBA 06/2010 - 03/2010
2	Kainic Acid (Kainate)IBA 01/2007 - 08/2006
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	Neuroprotective AgentsIBA 01/2022
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022
1	enhanced green fluorescent proteinIBA 01/2022
1	ParvalbuminsIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Fentanyl (Sublimaze)FDA LinkGeneric 10/2021
1	Narcotics (Narcotic Analgesics)IBA 10/2021
1	MRI-1867IBA 01/2021
1	Opioid Receptors (Opioid Receptor)IBA 01/2021
1	Interleukin-11 (Interleukin 11)IBA 01/2021
1	Naloxone (Narcan)FDA LinkGeneric 11/2020
1	gonadotropin-releasing hormone-IIIIBA 12/2019

Therapy/Procedure

10	Therapeutics 01/2022 - 07/2006
7	Drug Therapy (Chemotherapy) 01/2022 - 03/2015
4	Ligation 01/2019 - 12/2006
1	Pain Management 10/2021